In vitro culture of HER2 + breast cancer cells treated with anti-Her2-MSN produced a spike in the US contrast around 640% with a boundary thickness of 1 mm proving their capacity to improve US imaging in these tumors. Here, ERBB2 is linked to breast carcinoma.